PedAM
Pediatric Disease Annotations & Medicines
| Disease | schizophrenia |
| Symptom | C0686347|tardive dyskinesia |
| Sentences | 15 |
| PubMedID- 25336319 | Possible association between dbh 19 bp insertion/deletion polymorphism and clinical symptoms in schizophrenia with tardive dyskinesia. |
| PubMedID- 19740630 | Signs of striatal dopamine transporter density increase in association with improvement of tardive dyskinesia in a patient with schizophrenia, as demonstrated by a dat scan. |
| PubMedID- 25717485 | tardive dyskinesia in patients with schizophrenia treated with olanzapine - results from a 20-month, prospective, open study under naturalistic conditions. |
| PubMedID- 20398909 | Reduced status of plasma total antioxidant capacity in schizophrenia with tardive dyskinesia. |
| PubMedID- 24325977 | Cognition impairment in schizophrenia patients with tardive dyskinesia: association with plasma superoxide dismutase activity. |
| PubMedID- 24994553 | Altered bdnf is correlated to cognition impairment in schizophrenia patients with tardive dyskinesia. |
| PubMedID- 24995685 | Reduced serum tnf alpha level in chronic schizophrenia patients with or without tardive dyskinesia. |
| PubMedID- 25954194 | However, a 12 week double-blind placebo controlled study providing 2 g/day epa in schizophrenia patients with established tardive dyskinesia failed to demonstrate any anti-dyskinetic effects, although modest and transient benefits were seen in recent onset patients (emsley et al., 2006). |
| PubMedID- 21612745 | Objective: the aim of the study was to survey the frequency of tardive dyskinesia (td) in patients with schizophrenia and its demographic and clinical correlates in selected asian countries. |
| PubMedID- 25151339 | Association of altered cuzn superoxide dismutase and cognitive impairment in schizophrenia patients with tardive dyskinesia. |
| PubMedID- 22071797 | Objectives: to determine the effects of calcium-channel blocker drugs (diltiazem, nifedipine, nimodipine, verapamil) for treatment of neuroleptic-induced tardive dyskinesia in people with schizophrenia, schizoaffective disorder or other chronic mental illnesses. |
| PubMedID- 23967150 | Gray matter abnormalities in schizophrenia patients with tardive dyskinesia: a magnetic resonance imaging voxel-based morphometry study. |
| PubMedID- 25866243 | Objectives: to determine the effectiveness of pyridoxal 5 phosphate (vitamin b6 or pyridoxine or pyridoxal phosphate) in the treatment of neuroleptic-induced tardive dyskinesia among people with schizophrenia and other related psychotic disorders. |
| PubMedID- 25600548 | Altered il-2, il-6 and il-8 serum levels in schizophrenia patients with tardive dyskinesia. |
| PubMedID- 23918915 | The authors present a case of a 29-year-old woman who presented to a family medicine clinic for ongoing management of schizophrenia with noticeable tardive dyskinesia and complaints of neck and upper back pain. |
Page: 1